Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gastric mucosal layer glycoproteins consist mainly of secreted, high-molecular-weight mucins, with Mucin-5AC and Mucin-6 being the principal components in the stomach. These gel-forming, O-glycosylated proteins are secreted by epithelial cells to create a thick, viscoelastic barrier atop the gastric epithelium[3][6][5]. This layer protects the stomach lining from corrosive acid, digestive enzymes, pathogens, and mechanical friction caused by food. The structure and glycosylation pattern of these mucins are dynamic and can be altered in diseases like gastritis, gastric ulcer, Helicobacter pylori infection, and gastric cancer[3][6][4]. Although drugs may influence mucin secretion or the integrity of the mucus barrier, these glycoproteins themselves are not typically direct molecular drug targets. This entity is not a classical drug target but refers to a physiological barrier composed of mucin family glycoproteins, most prominently Mucin-5AC and Mucin-6[3][6][5].
Not applicable as a direct target. Drugs may increase mucin secretion or stabilize mucus gel indirectly[5]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastric mucosal layer glycoproteins.